[{"id":"bd7ac170-f9ec-4021-bd06-e5f2697c1c6d","acronym":"ELU-FRα-1","url":"https://clinicaltrials.gov/study/NCT05001282","created_at":"2021-08-11T14:55:40.694Z","updated_at":"2024-07-02T16:35:12.374Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","source_id_and_acronym":"NCT05001282 - ELU-FRα-1","lead_sponsor":"Elucida Oncology","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELU001"],"overall_status":"Recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-28"},{"id":"c64e5bc4-4269-4e29-8344-c838b81cc443","acronym":"Pediatric AML","url":"https://clinicaltrials.gov/study/NCT05622591","created_at":"2022-11-18T14:59:38.203Z","updated_at":"2024-07-02T16:35:26.706Z","phase":"Phase 1","brief_title":"ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML","source_id_and_acronym":"NCT05622591 - Pediatric AML","lead_sponsor":"Elucida Oncology","biomarkers":" CBFA2T3 • GLIS2","pipe":"","alterations":" ","tags":["CBFA2T3 • GLIS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELU001"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-12-08"}]